We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Lilly(Eli) | LSE:LEL | London | Ordinary Share | COM STK NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.5373 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
Hot Features
Premium
Press Release
Annual Information Update
Lilly (Eli) & Co
24 January 2013
Eli Lilly and Company
(the "Company")
Annual Information Update for the 12 months up to and including 24 February 2012.
This Annual Information Update refers to information that has been published or made available to the public in European Economic Area states and in third countries in compliance with the Company's obligations under EU and national laws and rules dealing with the regulation of securities, issuers of securities and securities markets. The Company is obliged to provide this Annual Information Update by virtue of having transferable securities listed or admitted to trading on regulated markets in London.
Neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information which this Annual Information Update contains. This information is not necessarily up to date as at the date of this Annual Information Update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. This Annual Information Update does not constitute an offer of any securities addressed to any person and should not be relied on by any person.
1. FILINGS IN THE UNITED KINGDOM
The following documents have been filed with the National Storage Mechanism:
Filing Date Description
17 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co CHMP
Recommends Approval BYETTA for Use w/Basal Insulin
7 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co New Study
Evaluates Cialis® in parallel with Tamsulosin
1 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co FDA approves
Jentadueto
1 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports
Fourth-Quarter and Full-Year 2011 Results
31 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports
Fourth-Quarter and Full-Year 2011 Results
31 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co FDA approves
Jentadueto
24 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co Lillys
Agreement to Acquire ChemGen Corp.
5 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co 2012 Financial
Guidance
16 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Sets
Conference Calls for 2012 Financial Guidance
13 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Declares
First-Quarter 2012 Dividend
12 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Findings From
Study of JAK2 Inhibitor for Blood Cancers
12 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Katherine
Baicker Elected to Lilly Board of Directors
17 November 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Data Shows
Effects of Effient in STEMI Patients
8 November 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly and
Amylin Agree to End Alliance for Exenatide
28 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ALIMTA
Receives EC Approval
25 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Xigris Recall
- Financial Press Release
25 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Withdrawal of
Xigris
20 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports
Third Quarter 2011 Results
18 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Dividend
Declaration - Dividend Declaration
12 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co LVHR Phase III
Study
11 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Statement re
Changes in Senior Management - Statement re
27 September 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Alimta - New
Data from Paramount Study
26 September 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Alimta
Receives Positive Opinion from CHMP
29 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co US Court of
Appeals Affirms Validity of Strattera Patent
28 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Bydureon Reply
Submitted To FDA
22 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Cymbalta
Chronic Pain CHMP Opinion
21 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports
Second-Quarter 2011 Results
1 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Walsh
Appointed to Company's Executive Committee
30 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co 2011 Lilly
Investment Community Meeting
27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co BYDUREON Not
Associated with Relevant QT Prolongation
27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co BYETTA Lower
Likelihood of Heart Failure
27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Effect of
BYDUREON on A1C and Weight
27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Once-Monthly
EXENATIDE Improved Glucose Control
24 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Linagliptin
recommended in Europe for Type II diabetes
21 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Dividend
Declaration - Dividend Declaration
9 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co US Court Rules
in Favor of Lilly in Amylin Litigation
8 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co FDA Approves
Updates to Lillys Humalog Label
26 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Comments
on Court Ruling in Amylin Litigation
23 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly &
Investor Grp Form Critical Care Co BioCritica
19 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011
Cixutumumab Release
19 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011 BAFF
Release
17 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Provides
Its Perspective in Re to Amylin Lawsuit
16 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Statement in
Response to Amylin Lawsuit - Response to
16 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011
Pipeline
16 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011
Branded Products
3 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Tradjenta
Approval
28 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly
Maintains Patent Exclusivity for Cymbalta
26 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly
Medtronic Collaboration
19 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Receives
Response Letter from FDA for Liprotamase
19 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Dividend
Declaration - Dividend Declaration
18 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co 1st Quarter
Results- 1st Quarter Results
18 April 2011 Eli Lilly and Company - Issuer Document- Proxy Form
18 April 2011 Eli Lilly and Company - Issuer Document- Proxy Form
15 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co BYDUREON
Recommended For Approval In Europe
7 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Public Alert
Press Release Q111
4 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Axiron®
topical solution CIII
18 March 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Amyvid FDA
Action
14 March 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Makes
Offer to Acquire Janssen Animal Health - Offer
3 March 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co DURATION-6
Top-Line Study Results Announced
24 February 2011 Eli Lilly and Company - Issuer Document - Prospectus
(excluding RNA)
Full details of the above filings can be found on the National Storage Mechanism's website at http://www.morningstar.co.uk/uk/NSM.
2. FILINGS IN THE UNITED STATES
The Company also submitted the following filings with the United States Securities and Exchange Commission ("SEC") in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having securities registered under the U.S. Securities Exchange Act 1934:
Filing Date Forms Description SEC Filing
Group
24 February 2012 10-K Annual report which provides a Annual
comprehensive overview of the company Filings
for the past year
16 February 2012 SC 13G/A Statement of acquisition of SC 13
beneficial ownership by individuals
(Amendment)
16 February 2012 5 Annual statement of changes in 3,4,5
beneficial ownership of securities
15 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
13 February 2012 SC 13G/A Statement of acquisition of SC 13
beneficial ownership by individuals
(Amendment)
10 February 2012 SC 13G/A Statement of acquisition of SC 13
beneficial ownership by individuals
(Amendment)
3 February 2012 PRE 14A Other preliminary proxy statements Proxy
Statement
2 February 2012 5 Annual statement of changes in 3,4,5
beneficial ownership of securities
2 February 2012 5 Annual statement of changes in 3,4,5
beneficial ownership of securities
2 February 2012 5 Annual statement of changes in 3,4,5
beneficial ownership of securities
2 February 2012 5 Annual statement of changes in 3,4,5
beneficial ownership of securities
2 February 2012 4/A Statement of changes in beneficial 3,4,5
ownership of securities - Amendment
2 February 2012 4/A Statement of changes in beneficial 3,4,5
ownership of securities - Amendment
2 February 2012 4/A Statement of changes in beneficial 3,4,5
ownership of securities - Amendment
2 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 February 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
31 January 2012 8-K Report of unscheduled material events Current
or corporate event Reports
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
11 January 2012 3 Initial statement of beneficial 3,4,5
ownership of securities
11 January 2012 3 Initial statement of beneficial 3,4,5
ownership of securities
6 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
5 January 2012 8-K/A Report of unscheduled material events Current
or corporate event - Amendment Reports
5 January 2012 8-K Report of unscheduled material events Current
or corporate event Reports
3 January 2012 4 Statement of changes in beneficial 3,4,5
ownership of securities
20 December 2011 4/A Statement of changes in beneficial 3,4,5
ownership of securities - Amendment
14 December 2011 3 Initial statement of beneficial 3,4,5
ownership of securities
14 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
12 December 2011 8-K Report of unscheduled material events Current
or corporate event Reports
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4/A Statement of changes in beneficial 3,4,5
ownership of securities - Amendment
1 December 2011 4/A Statement of changes in beneficial 3,4,5
ownership of securities - Amendment
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 December 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
21 November 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
14 November 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 November 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
28 October 2011 10-Q Quarterly report which provides a Quarterly
continuing view of a company's Filings
financial position
20 October 2011 8-K Report of unscheduled material events Current
or corporate event Reports
13 October 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
3 October 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
3 October 2011 4/A Statement of changes in beneficial 3,4,5
ownership of securities - Amendment
30 September 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
14 September 2011 8-K/A Report of unscheduled material events Current
or corporate event - Amendment Reports
14 September 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
12 September 2011 UPLOAD SEC-generated letter Other
1 September 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
31 August 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
12 August 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
10 August 2011 CORRESP Correspondence Other
3 August 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
29 July 2011 10-Q Quarterly report which provides a Quarterly
continuing view of a company's Filings
financial position
25 July 2011 CORRESP Correspondence Other
21 July 2011 8-K Report of unscheduled material events Current
or corporate event Reports
13 July 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
13 July 2011 UPLOAD SEC-generated letter Other
8 July 2011 3 Initial statement of beneficial 3,4,5
ownership of securities
8 July 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 July 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
30 June 2011 8-K Report of unscheduled material events Current
or corporate event Reports
28 June 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
22 June 2011 CORRESP Correspondence Other
22 June 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
15 June 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
2 June 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
1 June 2011 CORRESP Correspondence Other
24 May 2011 UPLOAD SEC-generated letter Other
18 May 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
18 May 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
13 May 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
10 May 2011 CORRESP Correspondence Other
2 May 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
29 April 2011 10-Q Quarterly report which provides a Quarterly
continuing view of a company's Filings
financial position
19 April 2011 8-K Report of unscheduled material events Current
or corporate event Reports
18 April 2011 8-K Report of unscheduled material events Current
or corporate event Reports
14 April 2011 CORRESP Correspondence Other
13 April 2011 UPLOAD SEC-generated letter Other
12 April 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
4 April 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
14 March 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
10 March 2011 SC 13G/A Statement of acquisition of SC 13
beneficial ownership by individuals -
Amendment
8 March 2011 ARS Annual Report to Security Holders Annual
Filings
8 March 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
7 March 2011 DEF 14A Other definitive proxy statements Proxy
Statements
2 March 2011 4 Statement of changes in beneficial 3,4,5
ownership of securities
24 February 2011 S-8 Securities to be offered to employees Registration
in employee benefit plans Statements
Full details of the above regulatory announcements can be found on the SEC website at http://www.sec.gov.
CONTACT:
Jamie E. Haney
Counsel - Corporate Securities and Assistant Secretary
(317) 277-3278 (317) 407-1288 (M) haney_jamie_e@lilly.com LONDONAVINCE23599249.01 9 1233315-v2NYCDMS LONDONAVINCE23599249.01
Copyright y 24 PR Newswire
1 Year Lilly(Eli) Chart |
1 Month Lilly(Eli) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
